List of Veletri drug patents

Veletri is owned by Actelion.

Veletri contains Epoprostenol Sodium.

Veletri has a total of 2 drug patents out of which 0 drug patents have expired.

Veletri was authorised for market use on 27 June, 2008.

Veletri is available in injectable;injection dosage forms.

The generics of Veletri are possible to be released after 15 March, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598227 ACTELION Epoprostenol formulation and method of making thereof
Feb, 2027

(3 years from now)

US8318802 ACTELION Epoprostenol formulation and method of making thereof
Mar, 2027

(4 years from now)

Drugs and Companies using EPOPROSTENOL SODIUM ingredient

Market Authorisation Date: 27 June, 2008

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of VELETRI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in